Aegis Capital Keeps Their Buy Rating on Ocera Therapeutics

By Ryan Adsit

Aegis Capital analyst Difei Yang reiterated a Buy rating on Ocera Therapeutics (NASDAQ: OCRX) today and set a price target of $3. The company’s shares closed yesterday at $1.14.

According to, Yang is a 4-star analyst with an average return of 5.9% and a 44.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Protalix Biotherapeutics, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Ocera Therapeutics is Moderate Buy and the average price target is $3.50, representing a 207.0% upside.

In a report issued on May 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $4 price target.

The company has a one year high of $3.15 and a one year low of $0.52. Currently, Ocera Therapeutics has an average volume of 2.34M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in development and commercialization of OCR-002 (ornithine phenylacetate0 in intravenous and oral formulations. The company was founded by Wu Xiaoyun, John C. Kappes, and Eckard Weber on January 12, 1998 and is headquartered in Palo Alto, CA.